Foghorn Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FHTX research report →
Companyfoghorntx.com
Foghorn Therapeutics Inc. , a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
- CEO
- Adrian H. Gottschalk
- IPO
- 2020
- Employees
- 112
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $228.98M
- P/E
- -3.60
- P/S
- 8.11
- P/B
- -3.55
- EV/EBITDA
- -2.52
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 22.26%
- Op Margin
- -286.16%
- Net Margin
- -266.88%
- ROE
- 85.78%
- ROIC
- -50.60%
Growth & Income
- Revenue
- $30.91M · 36.75%
- Net Income
- $-74,283,000 · 14.24%
- EPS
- $-1.18 · 25.32%
- Op Income
- $-82,107,000
- FCF YoY
- 14.97%
Performance & Tape
- 52W High
- $6.95
- 52W Low
- $3.27
- 50D MA
- $4.79
- 200D MA
- $4.97
- Beta
- 2.97
- Avg Volume
- 174.43K
Get TickerSpark's AI analysis on FHTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 10, 26 | GOTTSCHALK ADRIAN | other | 59,208 |
| Apr 10, 26 | GOTTSCHALK ADRIAN | other | 59,208 |
| Apr 9, 26 | GOTTSCHALK ADRIAN | other | 47,497 |
| Apr 9, 26 | GOTTSCHALK ADRIAN | other | 47,497 |
| Feb 23, 26 | Maynard Ryan D | other | 400,000 |
| Feb 23, 26 | Maynard Ryan D | other | 0 |
| Feb 5, 26 | GOTTSCHALK ADRIAN | other | 1,075,000 |
| Jan 30, 26 | Costa Carlos | other | 230,000 |
| Jan 30, 26 | LaCascia Michael | other | 295,000 |
| Jan 30, 26 | Cardama Alfonso Quintas | other | 300,000 |
Our FHTX Coverage
We haven't published any research on FHTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FHTX Report →